PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
204.50
P/E of 204.50 versus zero earnings in Healthcare. Walter Schloss would verify earnings quality.
No Data
No Data available this quarter, please select a different quarter.
-214.06
Negative equity while Healthcare median P/B is 1.77. Seth Klarman would investigate balance sheet restructuring potential.
1843.78
P/FCF of 1843.78 versus zero FCF in Healthcare. Walter Schloss would verify cash flow quality.
1843.78
P/OCF of 1843.78 versus zero operating cash flow in Healthcare. Walter Schloss would verify operational quality.
-214.06
Negative fair value while Healthcare median is 1.78. Seth Klarman would investigate valuation model issues.
0.12%
Earnings yield 75-90% of Healthcare median of 0.14%. John Neff would demand superior growth to justify lower yield.
0.05%
Positive FCF while Healthcare median shows negative FCF. Peter Lynch would examine cash generation advantage.